McKesson Co. (NYSE:MCK - Free Report) - Analysts at Zacks Research boosted their Q3 2025 EPS estimates for McKesson in a report released on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the company will post earnings of $8.30 per share for the quarter, up from their previous estimate of $8.24. The consensus estimate for McKesson's current full-year earnings is $32.73 per share. Zacks Research also issued estimates for McKesson's Q4 2025 earnings at $9.17 EPS, FY2025 earnings at $32.43 EPS, Q1 2026 earnings at $7.92 EPS, Q3 2026 earnings at $10.02 EPS and Q4 2026 earnings at $8.99 EPS.
Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upped their price target on shares of McKesson from $656.00 to $661.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Barclays raised their target price on McKesson from $596.00 to $616.00 and gave the stock an "overweight" rating in a research report on Thursday, August 8th. Leerink Partners dropped their price target on McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a research report on Monday, October 7th. StockNews.com upgraded McKesson from a "hold" rating to a "buy" rating in a research report on Wednesday, November 6th. Finally, Citigroup increased their price target on shares of McKesson from $630.00 to $713.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $631.57.
Check Out Our Latest Stock Analysis on McKesson
Shares of MCK opened at $628.50 on Monday. McKesson has a 1-year low of $431.35 and a 1-year high of $637.51. The business's 50-day moving average price is $542.22 and its 200 day moving average price is $560.02. The stock has a market capitalization of $79.78 billion, a P/E ratio of 32.55, a P/E/G ratio of 1.36 and a beta of 0.44.
McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business had revenue of $93.65 billion for the quarter, compared to analysts' expectations of $89.33 billion. During the same period in the previous year, the firm posted $6.23 EPS. The company's quarterly revenue was up 21.3% on a year-over-year basis.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Monday, December 2nd. McKesson's dividend payout ratio is 14.71%.
In other news, CEO Brian S. Tyler sold 3,753 shares of the firm's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total value of $2,105,808.30. Following the sale, the chief executive officer now directly owns 78,586 shares of the company's stock, valued at approximately $44,094,604.60. This trade represents a 4.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.11% of the company's stock.
Large investors have recently bought and sold shares of the stock. Wolff Wiese Magana LLC lifted its stake in shares of McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock valued at $29,000 after buying an additional 52 shares during the period. MidAtlantic Capital Management Inc. bought a new position in McKesson in the third quarter worth $29,000. RPg Family Wealth Advisory LLC acquired a new position in shares of McKesson in the 3rd quarter valued at $31,000. ORG Wealth Partners LLC acquired a new stake in shares of McKesson during the 3rd quarter valued at about $40,000. Finally, Carmichael Hill & Associates Inc. bought a new position in McKesson during the second quarter worth about $52,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.